ATS Corp /ATS

ATS Corporation announced the election of all nominee directors at its Annual and Special Meeting of Shareholders held on August 6, 2026, with 88.12% of common shares represented. The company also provided an update on its Normal Course Issuer Bid (NCIB), stating it has purchased 146,085 common shares at an average price of $29.08, totaling approximately $4.25 million. ATS is authorized to repurchase up to 8,225,621 common shares for cancellation under the NCIB, which is active until December 21, 2026.

ATS Corporation held its Annual Meeting of Shareholders on August 6, 2026, where shareholders approved the election of all nominated directors and the re-appointment of Ernst & Young LLP as auditors. The company's approach to executive compensation was also approved through a non-binding resolution. A shareholder proposal to amend By-Law No.1 was not approved by the shareholders.

ATS Corp reported a net loss of $0.3 million for Q1 fiscal 2027, a significant decline from a $24.3 million net income in the prior year, with revenues decreasing 5.8% to $693.7 million. The company initiated a Fixed Cost Transformation Program, including a European Footprint Consolidation, aiming to reduce annual costs by at least $20 million and achieve a 15% long-term adjusted earnings from operations margin. This restructuring is intended to simplify operations, optimize its global footprint, and better align with growth objectives despite near-term challenges in order bookings and project execution.

ATS Corporation announced it will report its first quarter results for the period ended June 28, 2026, before markets open on August 06, 2026. The company will host a conference call and webcast for management's remarks and a Q&A session on the same day at 8:30 a.m. Eastern. Additionally, ATS will hold its Annual Meeting of Shareholders virtually on August 06, 2026, at 10:30 a.m. Eastern.

ATS Corp filed a Form 6-K with the SEC, providing various documents related to its upcoming Annual General Meeting. These exhibits include the Management Information Circular, Notice of Meeting, and proxy materials. The filing ensures shareholders have access to necessary information for the meeting.

ATS Corporation announced that management will participate in the Stifel Summer Solstice Conference in Muskoka, ON on June 16, 2026. Institutional investor meetings will be hosted at the conference. Interested parties can arrange meetings by contacting their Stifel representative or David Ocampo, Head of Investor Relations.

ATS Corporation reported fourth quarter fiscal 2026 revenues of $747.1 million, a 30.1% increase year-over-year, with net loss narrowing significantly to $16.2 million from $68.9 million in the prior year. For the full fiscal year 2026, revenues grew 17.4% to $2,972.9 million, achieving a net income of $71.7 million compared to a loss of $28.0 million last year. The company undertook decisive steps to restructure its transportation-related businesses, consolidating operations and right-sizing its facility footprint, incurring $15.2 million in restructuring charges for the quarter. ATS expects modest revenue growth and a 50-75 basis point improvement in adjusted earnings from operations margin for fiscal 2027, with Q1 2027 revenues projected between $700 million and $740 million.

ATS Corporation announced it will report its financial results for the fourth quarter ended March 31, 2026, before markets open on Thursday, May 28, 2026. The company will host a conference call and webcast on the same day at 8:30 a.m. Eastern to discuss the results and conduct a Q&A session with analysts. Replay options will be available for one week following the call.

ATS Corporation has filed an Indenture to establish the framework for the future issuance of its unsecured debentures, notes, or other evidences of indebtedness. This legal document ensures compliance with the Trust Indenture Act of 1939 and details the terms, conditions, and responsibilities governing these potential securities. It covers various aspects from definitions and security forms to remedies, covenants, and the roles of the Company and the Trustee.